Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05502133 · ClinicalTrials.gov registry record
Identification of Acute Intermittent Porphyria Modifying Genes
A clinical trial of Acute Intermittent Porphyria (AIP), sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT05502133: Recruiting study of Acute Intermittent Porphyria (AIP), sponsored by Icahn School of Medicine at Mount Sinai.
NCT05502133 is a study of Acute Intermittent Porphyria (AIP) that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 150 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05502133, a study of Acute Intermittent Porphyria (AIP), is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study proposes to identify the predisposing/protective modifying genes that underlie the acute attacks in symptomatic patients with Acute Intermittent Porphyria (AIP), an autosomal dominant inborn error of heme biosynthesis.
Primary Outcome
There are no primary and secondary endpoints. This is an exploratory genetic study. Exploratory Endpoints: Odds ratios (OR) of the effects of identified modifier genes/variants. (If putative predisposing or protective gene variants are identified)
Conditions Studied
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-09-23 |
| Est. Completion | 2026-06 |
What NCT05502133 shows while recruiting
NCT05502133 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Acute Intermittent Porphyria (AIP) appearing as the primary indexed condition, and to 0 interventions.
NCT05502133 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05502133 about?
NCT05502133 is a clinical study titled "Identification of Acute Intermittent Porphyria Modifying Genes". This study proposes to identify the predisposing/protective modifying genes that underlie the acute attacks in symptomatic patients with Acute Intermittent Porphyria (AIP), an autosomal dominant inborn error of heme biosynthesis.
What is the current status of trial NCT05502133?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2022-09-23. Estimated completion is 2026-06.
What conditions does trial NCT05502133 study?
This clinical trial studies the following conditions: Acute Intermittent Porphyria (AIP).
Who is sponsoring clinical trial NCT05502133?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05502133 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI